| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2025 | Aug 7, 2025 | Bausch & Lomb Corp | CEO | Sell | 45.0 | -4,231 | -0.57% | ✗ | $61.1K |
| May 22, 2025 | May 27, 2025 | Bausch & Lomb Corp | CEO | Buy | 90.0 | +44,000 | 6.31% | ✗ | $248.1K |
| May 20, 2025 | May 22, 2025 | ARS Pharmaceuticals, Inc. | Director | Sell | 17.5 | -120,000 | -100.00% | ✗ | $1.7M |
| Dec 23, 2024 | Dec 26, 2024 | Bausch & Lomb Corp | CEO | Sell | 37.5 | -98,431 | -15.69% | ✗ | $1.8M |
| Aug 12, 2024 | Aug 13, 2024 | Beauty Health Co | Director | Buy | 61.3 | +40,450 | 0.47% | ✗ | $43.7K |
| Aug 5, 2024 | Aug 7, 2024 | Bausch & Lomb Corp | CEO | Buy | 97.5 | +64,500 | 11.46% | ✗ | $505.1K |
| Mar 31, 2022 | Jul 10, 2024 | Beauty Health Co | Director | Sell | 75.0 | +53,866 | 0.62% | ✗ | $322.2K |
| Aug 16, 2023 | Aug 17, 2023 | Beauty Health Co | Director | Buy | 75.0 | +59,380 | 0.69% | ✗ | $362.4K |
| Jan 27, 2022 | Jan 31, 2022 | Beauty Health Co | Director | Sell | 47.5 | -6,812 | -0.08% | ✗ | $83.4K |
| Dec 29, 2021 | Jan 3, 2022 | BridgeBio Pharma, Inc. | Director | Buy | 97.5 | +17,600 | 100.00% | ✗ | $254.9K |